Log in with your email address username.


[Correspondence] Is discussion of dengue vaccination for the 2016 Olympics necessary?

Scott Halstead and Maira Aguiar’s correspondence (July 16, p 237)1 about the Rio 2016 Olympic Games and the Sanofi Pasteur dengue vaccine (Dengvaxia), discusses in the second half the role of antibody-dependent enhancement in the observed imbalance in dengue cases in 2–5-year-old children during Year 3 of the Asian CYD14 trial.2 Although the link between this second part of the correspondence and the Olympic Games is not obvious, we would like to provide our thoughts on this matter.